Vanguard Capital Management
HOWL icon

Vanguard Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Vanguard Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Hold
1,217,976
– – ﹤0.01% 3729
2026
Q1 		$1.01M Buy
+1,217,976
New +$834K ﹤0.01% 3548

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's HOWL Position: Q2 2026 in Review

Vanguard Capital Management held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 1,217,976 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #3729.

Vanguard Capital Management first reported a position in HOWL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.01M in Q1 2026. 42 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Vanguard Capital Management held 1,217,976 shares of Werewolf Therapeutics worth $438K as of Q2 2026.
  • Vanguard Capital Management left its Werewolf Therapeutics share count unchanged in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3729 holding.
  • Vanguard Capital Management first reported a position in Werewolf Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Werewolf Therapeutics position peaked at $1.01M in Q1 2026.
  • 42 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.